Related Experiment Video
Updated: Oct 22, 2025

Comparing Objective Conjunctival Hyperemia Grading and the Ocular Surface Disease Index Score in Dry Eye Syndrome During COVID-19
Published on: May 25, 2022
Erythema Multiforme and COVID-19: What Do We Know?
Luigi Bennardo1,2, Steven Paul Nisticò1, Stefano Dastoli1
1Department of Health Sciences, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy.
Insights
Erythema multiforme (EM), a skin rash, rarely occurs with COVID-19, often due to a hypersensitivity reaction. This review suggests three types of EM linked to COVID-19: virus-related juvenile, virus-related older, and drug-induced.
Area of Science:
- Dermatology
- Infectious Diseases
- Virology
Background:
- Erythema multiforme (EM) is an acute skin eruption.
- It is commonly linked to infections and occasionally drugs.
- The association between EM and COVID-19 requires further investigation.
Purpose of the Study:
- To systematically review and evaluate the association between erythema multiforme and COVID-19.
- To analyze the characteristics of EM in COVID-19 patients.
- To propose a classification for COVID-19-associated EM.
Main Methods:
- A systematic literature search was conducted across PubMed/MEDLINE, Scimago Scopus, and ISI/Web of Science.
- Original articles, case series, and case reports were selected for review.
- Data from 14 selected articles involving 70 patients were analyzed.
Main Results:
- Erythema multiforme rarely occurs in COVID-19 patients, usually due to hypersensitivity to the virus.
- EM associated with COVID-19 appears in distinct age groups: under 30 or over 55.
- Hydroxychloroquine is an infrequent drug-induced cause of EM in COVID-19 management.
- Clinical characteristics and disease course differ among patient groups.
Conclusions:
- COVID-19-associated EM can be preliminarily classified into three types: virus-related juvenile (<30 years), virus-related older (>55 years), and drug-induced.
- Skin rash occurrence does not correlate with COVID-19 severity or clinical course.
Abstract:
Background: Erythema multiforme (EM) is an acute cutaneous eruption often associated with infections and more rarely with drugs. This review aimed to evaluate the association between erythema multiforme and coronavirus disease 2019 (COVID-19). Methods: A systematic search of PubMed/MEDLINE, Scimago Scopus, and ISI/Web of Science was performed. Original articles, case series, or case reports were evaluated and selected. Results: Fourteen articles were selected, describing a total of 70 patients. EM is a cutaneous eruption rarely occurring in COVID-19 and is, in most cases, associated with a hypersensitivity reaction to the virus. In these cases, EM seems to affect patients younger than 30 years or older than 55 years. Infrequently, some drugs used in the management of COVID-19 may induce EM, especially hydroxychloroquine. The three groups of patients seem to have different clinical characteristics and courses. Conclusions: From these data, it is possible to preliminarily propose that EM or EM-like eruptions linked to COVID-19 might be divided into three types: the virus-related juvenile type (affecting patients <30-year-old), the virus-related older type (affecting patients >55 years), and the drug-induced type. The occurrence of a skin rash does not seem to be related to the severity and clinical course of COVID-19.
Related Concept Videos
Myocarditis III: Medical Management
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis I: Introduction
Endocarditis II: Clinical Features of Infective Endocarditis
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease I: Introduction

